Harrow, Inc. HROW
Updated: 18 Jun 2026
No signal published yet
We already track Harrow and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Harrow, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Harrow free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 10, 2026, Harrow announced the re-launch of VERKAZIA, a prescription therapy for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. The company also reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million during its Q1 earnings call in May 2026.
What Firelda Watch includes for Harrow, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Harrow, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Harrow free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more